Skip to Content
Merck
CN

Develop the Next Generation of KRAS Inhibitors

Explore our organoid testing solutions


Test the efficacy of your compound(s) in a panel of 25 patient-derived organoids representing colorectal, lung, and pancreatic cancer. Our advanced screening capabilities include:

  • Direct measurement of cell viability with an image-based viability readout
  • High-throughput 3D assay format
  • Test any number of compounds, with no minimum number of models to enroll
  • High-dose quality with 10-point dose-response curves per compound
  • Inclusive of IC50 determination and heatmap generation

Accelerate your KRAS drug development with our comprehensive portfolio. Identify promising leads and understand compound mechanism of action to investigate and develop novel therapies. Book a consultation now!


KRASmut Panel Features

  • Largest commercially available KRASmut PDO panel, with 25 models that represent pivotal KRAS mutants including G12A, G12D, G12V, G13D and many others
  • Rigorously characterized with readily available RNA or DNA sequencing data
  • Diverse models encompassing both primary and metastatic tumors, with the ability to test off-tumor toxicities with matched normal organoids

Applying our KRASmut PDO Screen

Our meticulously designed KRASmut panel was instrumental in developing a clinical candidate using organoid technology targeting head & neck cancer. Discover our proof-of-concept study and learn how PDOs can be used to accelerate your preclinical therapeutic development.



Related Products

Loading